In glioblastoma, IL-10 promotes tumor proliferation and migration, with elevated levels correlating with malignancy (50–52), however, recent evidence indicates that IL 10 can paradoxically augment anti-tumor immunity by activating CD8+ T cells through the JAK1/STAT3 pathway, leading to enhanced granzyme B release and tumor lysis (58). The gene discussed is JAK1; the disease is neoplasm.